
. Monday, March 9, 2026 – 12:50 AM
New research suggests a potential link between GLP-1 medications – widely used to treat type 2 diabetes and obesity – and an increased risk of fractures, osteoporosis, and gout, particularly among adults over the age of 65.
GLP-1 Medications May Increase Osteoporosis and Gout Risk in Seniors
Dr. Michal Kasher-Miron, an endocrinologist at Meir Medical Center in Israel, told Fox News that older adults taking these medications face a greater fracture risk compared to those on other diabetes medications, with one study showing a relative increase of 11%.
“Advancing age and type 2 diabetes are both independent factors that increase the likelihood of osteoporotic fractures,” Dr. Kasher-Miron explained, highlighting the need for special attention to this patient group.
The study followed approximately 46,000 adults over 65 for three years and revealed a slight but statistically significant increase in fracture risk among GLP-1 users. This finding is critical as fractures can lead to hospitalization, loss of independence, and even increased mortality rates.
Separate research, presented at the American Academy of Orthopaedic Surgeons annual meeting, indicated that GLP-1 users had a 29% higher relative risk of developing osteoporosis over five years compared to non-users, along with a slight increase in gout incidence of 12%.
Researchers emphasized that the relationship between GLP-1 medications and bone health is observational, not causal. It remains unclear whether the risk is linked to rapid weight loss, dietary changes, muscle mass loss, or a direct effect on the bones themselves.
Dr. John Hornibrook, an associate professor of orthopedic surgery at the University of Pennsylvania, noted that the rapid weight loss associated with these drugs can reduce bone density similarly to the effects of zero gravity on astronauts. He as well explained that reduced calorie intake may lead to lower consumption of calcium, vitamin D, and protein – all essential for bone health.
Despite these potential risks, experts point out that GLP-1 medications have proven effective in controlling blood sugar, promoting weight loss, and reducing the risk of cardiovascular disease. They stress the importance of using these medications under medical supervision, with bone density screening and adequate nutrition and resistance exercise to support muscle and bone health during weight loss.
Novo Nordisk, a manufacturer of GLP-1 medications, stated that patient safety is a top priority and that they are working with the U.S. Food and Drug Administration. The company noted that known risks and benefits are outlined in the medication’s prescribing information, and that semaglutide has demonstrated additional benefits for the heart, kidneys, and liver when used under medical supervision.
